The data on BM samples with or without involvement of DLBCL of our cohort showed a downregulation of CXCR4 in the BM of patients under remission after therapy as well as the correlation of the CXCL12 expression with lymphoma cell infiltration underpins this assumption. Here, CXCL12 is linked to lymphoma.